Par Drugs & Chemicals Ltd

The 50-day moving average has crossed above the 200-day moving average for Par Drugs & Chemicals Ltd, signalling a golden cross on 11 Jun 2026. Yet, the stock declined 3.02% on the day this crossover occurred, while monthly indicators remain only mildly bullish or neutral. This divergence between the moving averages and price action calls for a detailed examination of the signal's reliability.

Par Drugs & Chemicals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 8 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 August 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Par Drugs & Chemicals Ltd has witnessed a significant improvement in its valuation parameters, transitioning from a very expensive rating to a fair valuation grade. This shift, driven primarily by a marked reduction in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positions the micro-cap chemical company as a more attractive proposition relative to its historical levels and peer group benchmarks.

Par Drugs & Chemicals Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, reflecting a positive change in market perception. With a current price of ₹99.30 and a recent day gain of 3.61%, the micro-cap chemical company is showing signs of renewed investor confidence amid a challenging sector backdrop.

Par Drugs & Chemicals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 July 2026, providing investors with an up-to-date view of its performance and outlook.

Par Drugs & Chemicals Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating. This change reflects a recalibration of price multiples such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the micro-cap chemical company more favourably against its peers and historical benchmarks.

Par Drugs & Chemicals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 19 July 2026, providing investors with the latest insights into its performance and outlook.

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Par Drugs & Chemicals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 16 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Par Drugs & Chemicals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating change occurred mid-May, the analysis below reflects the stock’s current position as of 01 June 2026, incorporating the latest fundamentals, returns, and financial metrics available today.

Par Drugs & Chemicals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Par Drugs & Chemicals Ltd., a Bhavnagar-based speciality chemicals manufacturer, reported a concerning fourth quarter for FY26, with net profit plunging 82.29% quarter-on-quarter to ₹0.85 crores from ₹4.80 crores in Q3 FY26. The sharp decline came despite the company maintaining a market capitalisation of ₹109.00 crores. The stock has reacted negatively to the results, trading at ₹88.30, down 4.68% and significantly below its 52-week high of ₹122.43.

Par Drugs & Chemicals Ltd has reported a significant deterioration in its financial trend for the quarter ended March 2026, with key metrics such as net sales, operating profit, and earnings per share hitting multi-quarter lows. This reversal from a previously positive trajectory has prompted a downgrade in the company’s mojo grade to Sell, reflecting growing concerns over its near-term prospects amid a challenging industry backdrop.

Par Drugs & Chemicals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date perspective on its performance and outlook.

Par Drugs & Chemicals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 27 April 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 29 April 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.